Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04400903
Other study ID # STUDY00021185
Secondary ID NCI-2020-03178ST
Status Terminated
Phase
First received
Last updated
Start date September 21, 2020
Est. completion date September 30, 2022

Study information

Verified date November 2022
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study examines heart rate monitoring variability for the early detection of pancreatic cancer. Pancreatic cancer is a very difficult disease to detect early. This study is being done to observe the heart rate variability in patients with pancreatic cancer compared to undiagnosed individuals with increased risk of developing pancreatic cancer. This may help researchers determine if pancreatic occurrences/recurrences (chance of coming back) can be detected sooner through monitoring heart rate and activity.


Description:

PRIMARY OBJECTIVES: I. To determine whether heart rate variability (HRV) is reduced in patients with pancreatic ductal adenocarcinoma (PDAC) compared with individuals at increased risk of developing PDAC. (Stage I) II. To assess the feasibility of long-term compliance using a wearable device. (Stage II) SECONDARY OBJECTIVES: I. To assess compliance with using a wearable device. (Stage I and II) II. To validate effectiveness of virtual device training. (Stage I and II) III. To determine whether HRV is reduced in participants at high-risk of developing PDAC. (Stage II) IV. To characterize timing and occurrence of PDAC among high-risk without disease. (Stage II) V. To characterize timing and occurrence of PDAC among participants at high-risk of developing PDAC. (Stage II) EXPLORATORY OBJECTIVES: I. To investigate the relationship between changes in HRV relative to sarcopenia-related body composition characteristics in PDAC patients. (Stage I) II. To investigate the relationship between the pNN50 HRV measure and PDAC diagnosis. (Stage I and II) III. To compare changes in sleep biometrics among all participants. (Stage I and II) IV. To evaluate changes in health-related quality of life assessments among all participants. (Stage I and II) V. To evaluate participant satisfaction with virtual device instruction. OUTLINE: Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.


Recruitment information / eligibility

Status Terminated
Enrollment 110
Est. completion date September 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: - Ability to understand and the willingness to sign an informed consent document - Own a smartphone that uses Android or Apple iOS operating systems - Participant must have one of the following: - Individuals with newly-diagnosed, treatment naive PDAC - all stages (applicable to Stage 1 only), or - Individuals with at least one of the following family phenotype and age will be included: - Two or more relatives with PDAC on the same side of the family, where 2 PDAC affected individuals are first-degree related (FDR) AND at least one PDAC-affected individual is an FDR of the subject; Age >= 50 years OR 10 years before onset in family - Two affected FDR with PDAC; Age >= 50 years OR 10 years before onset of an FDR - Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely pathogenic; Age >= 50 years OR 10 years before onset of an FDR or second-degree relative (SDR) - Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or likely pathogenic mutation variants in: p16, CDKN2A; Age >= 50 years - Known mutation carrier for STK11 (Peutz-Jeghers syndrome); Age >= 50 years - Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) with confirmed pathogenic or likely pathogenic variants in: MLH1, MSH2, MSH6, PMS2, or EPCAM; Age >= 50 years OR 10 years before onset of an FDR or SDR - Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic history of pancreatitis; Age >= 50 years Exclusion Criteria: - Any medical conditions that in the opinion of the investigators would compromise participant safety and/or the integrity of the data

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Activity Monitor
Undergo HRV monitoring via WHOOP device
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Complete questionnaires

Locations

Country Name City State
United States Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York
United States University of Nebraska Medical Center Omaha Nebraska
United States OHSU Knight Cancer Institute Portland Oregon

Sponsors (4)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute American Association for Cancer Research, National Cancer Institute (NCI), Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Magnitude of heart rate variability (HRV) decline (Stage I) As measured by root mean square of the successive differences (RMSSD) in pancreatic ductal adenocarcinoma (PDAC) patients and in high-risk participants. Up to 1 year after enrollment
Primary Compliance statistics for wristband use (Stage II) Defined as the percentage of days during which data were collected during at least 70% of the hours. Until onset of PDAC, study withdrawal, or death, whichever occurs first, assessed up to 5 years after enrollment
Secondary Compliance statistics for wristband use for all participants (Stage I, II) Defined as the percentage of days during which data were collected for at least 70% of the hours. Up to 6 weeks and 6 months after enrollment and device activation
Secondary Effectiveness of virtual training (Stage I, II) Defined as the percentage of participants for whom high quality data are available within 3 days of set up. The pattern of missing data, and the percentage of participants able to collect data will be presented graphically. Will also associate the compliance with patient characteristics, regions and seasons to understand what may impact the compliance rate. Up to 1 week after enrollment and device activation
Secondary Magnitude of HRV change (Stage II) As measured by RMSSD, in participants at high-risk of developing PDAC. Up to 5 years post enrollment
Secondary Incidence of PDAC among high-risk participants (Stage II) Up to 5 years post enrollment
Secondary Time of PDAC diagnosis among high-risk participants who developed PDAC (Stage II) Up to 5 years post enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT04969731 - Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer Phase 3
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05048524 - Peri-operative SLOG for Localized Pancreatic Cancer Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Completed NCT03257150 - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer N/A
Active, not recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Active, not recruiting NCT03267316 - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Terminated NCT04046887 - Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) Phase 1
Recruiting NCT05964621 - Venous Thromboembolism in Primary Pancreatic Tumour Resection
Active, not recruiting NCT04827953 - Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04291651 - UCSF PANC Cyst Registry
Recruiting NCT05977322 - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Active, not recruiting NCT04853017 - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Phase 1
Active, not recruiting NCT04862260 - Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma Early Phase 1
Completed NCT03770117 - Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
Completed NCT02259114 - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Phase 1
Recruiting NCT04146298 - Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer Phase 1/Phase 2